Johnson & Johnson announced Tuesday that a second shot of its vaccine boosts efficacy to 94% against moderate and severe COVID-19.
An independent FDA advisory panel has recommended a third dose of the Pfizer vaccine for people ages 65 and older and high-risk adults at 6 months after the second dose. The FDA is expected to make a final decision in coming days, CNBC reported.
“It is critical to prioritize protecting as many people as possible against hospitalization and death, given the continued spread of COVID-19,” Paul Stoffels, MD, chief scientific officer at Johnson & Johnson, said in the statement. “A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection, is crucial to vaccinating the global population,” he said. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.
CBS News: “Johnson & Johnson says study shows two doses of its vaccine offer 94% protection against COVID-19.” CNBC: “J&J says Covid booster shot is 94% effective in the U.S. when given two months after first dose.”
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
J&J says second shot boosts protection for moderate-severe COVID-19 to 94%Johnson & Johnson said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease.
Read more »
J&J says second shot boosts protection for moderate-severe Covid-19 to 94 percentThe company has now 'generated evidence that a booster shot further increases protection against Covid-19,' J&J’s chief scientific officer said Tuesday.
Read more »
J&J says second shot boosts protection for moderate-severe COVID-19 to 94%Johnson & Johnson said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease.
Read more »
2nd dose of J&J COVID-19 vaccine results in stronger protection, company saysThe new data, announced in a press release, adds to a growing body of evidence suggesting that booster shots could enhance vaccine protection against breakthrough infections -- though experts agree all three vaccines are still doing their job to protect against more serious illness. Compared to the Pfizer and Moderna vaccines, Johnson & Johnson's single-shot vaccine always had slightly lower efficacy. Peak efficacy from the two-shot Pfizer and Moderna vaccines was 95% and 94%, respectively, against symptomatic illness.
Read more »
Johnson & Johnson says COVID-19 booster shot 2 months after first increases protectionThe company has now 'generated evidence that a booster shot further increases protection against Covid-19,' J&J’s chief scientific officer said Tuesday.
Read more »